Trial Profile
Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Haemophagocytic lymphohistiocytosis
- Focus Therapeutic Use
- 29 Apr 2020 Status changed from active, no longer recruiting to completed.
- 04 Nov 2019 Planned End Date changed from 1 Nov 2020 to 1 Oct 2021.
- 04 Nov 2019 Status changed from recruiting to active, no longer recruiting.